KALSIOM is a biotech company based in Brest, France, discovering and developing first-in-class therapies to treat inflammatory auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need.The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in immune cells.
KALSIOM
Retrouvez nos autres références Biotechnology & Nutrition
Implantable medical device to treat certain forms of heart failure
Biotechnology & Nutrition
DessIA develops a Bot platform based on an Explainable AI to automate engineers tasks
Biotechnology & Nutrition
Management software specifically developed for roofers and carpenters
Biotechnology & Nutrition
Nos autres domaines d’intervention